학력
2004 – 2008년 서울대학교 화학부, 박사
1997년 – 2003년 서울대학교 화학부, 학사
주요경력
- 2009.1 – 2012.10 Scripps Research, 박사후연구원
- 2012.10 – 2016.3 Calibr-Skaggs at Scripps Research, 책임연구원
- 2016.4 – 2021.8 카이스트 생명과학과, 조교수
- 2021.9 – 2024.2 카이스트 생명과학과, 부교수
- 2024.3 – 현재 서울대학교 첨단융합학부 / 약학대학 약학과, 교수
주요관심 연구분야
I. Synthetic Immunology and Immunotherapy
II. Therapeutic Immune Cell Engineering
III. Next-generation Antibody Engineering
II. Therapeutic Immune Cell Engineering
III. Next-generation Antibody Engineering
대표논문자료
1. Redirection of CAR-T Cell Cytotoxicity Using Metabolic Glycan Labeling with Unnatural Sugars. Cha JH, Kim E, Lee HJ, Lee YH, Lee J, Kim E*, Kim CH*. J Med Chem. 2023 Jun 22;66(12):7804-7812
2. Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus. Lah S, Kim S, Kang I, Kim H, Hupperetz C, Jung H, Choi HR, Lee YH, Jang HK, Bae S, Kim CH*. J Immunother Cancer. 2023 Apr;11(4):e005519.
3. Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein. Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, Kim S, Lee Y, Han KH, Chung WS*, Kim CH*. Nat Med. 2022 Sep;28(9):1802-1812.
4. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH*. Mol Ther. 2022 Feb 2;30(2):579-592.
5. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG*, Kim CH*, Young TS*. Sci Adv. 2021 Aug 11;7(33):eabi8193.
6. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG*, Young TS*, Kim CH*, Cao Y. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8.
7. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Cao Y, Axup JY, Ma JS, Wang RE, Choi S, Tardif V, Lim RK, Pugh HM, Lawson BR, Welzel G, Kazane SA, Sun Y, Tian F, Srinagesh S, Javahishvili T, Schultz PG*, Kim CH*. Angew. Chem. Int. Ed. Engl. 2015 Jun 8;54(24):7022-7.
8. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, Gonzalez J, Schultz PG*, Young TS*, Kim CH*. J. Am. Chem. Soc. 2015 Mar 4;137(8):2832-5.
9. Bispecific small molecule-antibody conjugate targeting prostate cancer. Kim CH*, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG*.Proc. Natl. Acad. Sci. U S A. 2013 Oct 29;110(44):17796-801
10. Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids. Kim CH, Axup JY, Dubrovska A, Kazane SA, Hutchins BA, Wold ED, Smider VV*, Schultz PG*. J. Am. Chem. Soc. 2012 20;134(24):9918-21.
2. Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus. Lah S, Kim S, Kang I, Kim H, Hupperetz C, Jung H, Choi HR, Lee YH, Jang HK, Bae S, Kim CH*. J Immunother Cancer. 2023 Apr;11(4):e005519.
3. Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein. Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, Kim S, Lee Y, Han KH, Chung WS*, Kim CH*. Nat Med. 2022 Sep;28(9):1802-1812.
4. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Lee YH, Lee HJ, Kim HC, Lee Y, Nam SK, Hupperetz C, Ma JSY, Wang X, Singer O, Kim WS, Kim SJ, Koh Y, Jung I, Kim CH*. Mol Ther. 2022 Feb 2;30(2):579-592.
5. A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Schultz PG*, Kim CH*, Young TS*. Sci Adv. 2021 Aug 11;7(33):eabi8193.
6. Versatile strategy for controlling the specificity and activity of engineered T cells. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG*, Young TS*, Kim CH*, Cao Y. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8.
7. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers. Cao Y, Axup JY, Ma JS, Wang RE, Choi S, Tardif V, Lim RK, Pugh HM, Lawson BR, Welzel G, Kazane SA, Sun Y, Tian F, Srinagesh S, Javahishvili T, Schultz PG*, Kim CH*. Angew. Chem. Int. Ed. Engl. 2015 Jun 8;54(24):7022-7.
8. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, Gonzalez J, Schultz PG*, Young TS*, Kim CH*. J. Am. Chem. Soc. 2015 Mar 4;137(8):2832-5.
9. Bispecific small molecule-antibody conjugate targeting prostate cancer. Kim CH*, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG*.Proc. Natl. Acad. Sci. U S A. 2013 Oct 29;110(44):17796-801
10. Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids. Kim CH, Axup JY, Dubrovska A, Kazane SA, Hutchins BA, Wold ED, Smider VV*, Schultz PG*. J. Am. Chem. Soc. 2012 20;134(24):9918-21.
주요관심 연구분야
